2026-16730Presidential DocumentWallet

President Pushes Gold Standard Childhood Vaccine Recommendations Nationwide

Published Date: 8/14/2026

Presidential Document

Summary

No summary available.

Analyzed Economic Effects

4 provisions identified: 3 benefits, 0 costs, 1 mixed.

Federal 'Gold Standard' Vaccine List

The Order declares a set of "Gold Standard Childhood Vaccine Recommendations" and explicitly lists vaccines in three categories: (i) recommended for all children — measles, mumps, rubella, diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type B, pneumococcal disease, human papillomavirus, and varicella; (ii) recommended for certain high-risk groups — RSV monoclonal antibodies, hepatitis A, hepatitis B, meningococcal B, meningococcal ACWY, and dengue; and (iii) based on shared clinical decision-making — hepatitis A, hepatitis B, rotavirus, meningococcal disease, influenza, and COVID-19.

Option for Single‑Antigen MMR and Separate Visits

The Order directs HHS to present plans within 90 days to offer options to administer core childhood vaccines, starting with MMR, as single‑disease shots (the Order says MMR should be given in three separate single‑disease shots once such products are domestically available) and, to the maximum extent feasible, to administer childhood immunizations at separate medical visits while guaranteeing continued availability of combination vaccines.

Federal Legal Support for Parental Exemptions

The Order directs the Attorney General to take appropriate measures to further meritorious legal actions challenging State laws that conflict with constitutional and Federal statutory obligations related to parental authority, religious freedom, disability accommodations, and equal protection, including, where applicable under Federal law, States' obligations to provide religious and medical exemptions from childhood and adolescent immunization requirements; Departments of Justice, Education, and HHS must also act to ensure their contractors and grantees comply with those obligations.

Vaccine Safety Research and Monitoring Boost

The HHS Task Force must, within 90 days, present plans to develop additional alternative adjuvants to aluminum, conduct comparative safety and efficacy studies, ensure continuous evaluation of risk/benefit profiles using U.S. and international data, and improve vaccine safety monitoring, transparency, and research.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Effective Date
Published Date
8/10/2026
8/14/2026

Department and Agencies

Department
Independent Agency
Agency
Executive Office of the President
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register